Journal
THORAX
Volume 72, Issue 10, Pages 946-949Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2016-209397
Keywords
-
Categories
Funding
- Southampton NIHR Wellcome Trust Clinical Research Facility
- UK National Institute for Health Research
- Cancer Research UK [23562] Funding Source: researchfish
- National Institute for Health Research [CL-2011-26-004] Funding Source: researchfish
Ask authors/readers for more resources
The impact of immunosuppression on interferon-gamma release assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-alpha responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-gamma, IL-2 and TNF-alpha responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-alpha agents significantly impair interferon-gamma release assay performance. IP-10 may be a more robust TB biomarker than interferon-gamma in patients receiving corticosteroids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available